Reaction
B-Lymphocyte Abnormalities reporting signals
As of the last recalculation, B-Lymphocyte Abnormalities appears in 140 FAERS reports alongside 2 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 169.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 47 | 169.1 | 169.2 |
| Obinutuzumab | 15 | 151.7 | 151.8 |